The aim of the present study was to evaluate the interaction between depressive symptoms and metabolic dysregulations as risk factors for type 2 diabetes. The sample comprised of 2525 adults who participated in a baseline and a follow-up assessment over a 4.5-year period in the Emotional Health and Wellbeing Study (EMHS) in Quebec, Canada. A two-way stratified sampling design was used, on the basis of the presence of depressive symptoms and metabolic dysregulation (obesity, elevated blood sugar, high blood pressure, high levels of triglycerides and decreased high-density lipoprotein). A total of 87 (3.5%) individuals developed diabetes. Participants with both depressive symptoms and metabolic dysregulation had the highest risk of diabetes (adjusted odds ratio = 6.61, 95% confidence interval (CI): 4.86-9.01), compared with those without depressive symptoms and metabolic dysregulation (reference group). The risk of diabetes in individuals with depressive symptoms and without metabolic dysregulation did not differ from the reference group (adjusted odds ratio = 1.28, 95% CI: 0.81-2.03), whereas the adjusted odds ratio for those with metabolic dysregulation and without depressive symptoms was 4.40 (95% CI: 3.42-5.67). The Synergy Index (SI = 1.52; 95% CI: 1.07-2.17) suggested that the combined effect of depressive symptoms and metabolic dysregulation was greater than the sum of individual effects. An interaction between depression and metabolic dysregulation was also suggested by a structural equation model. Our study highlights the interaction between depressive symptoms and metabolic dysregulation as a risk factor for type 2 diabetes. Early identification, monitoring and a comprehensive management approach of both conditions might be an important diabetes prevention strategy. 
INTRODUCTION
Type 2 diabetes mellitus is a progressive chronic disease that is increasing at epidemic rates. A recent study found that the prevalence of diabetes worldwide has increased by 45% between 1990 and 2013. 1 Mental health problems often co-occur in people with type 2 diabetes. 2 Notably, three meta-analyses suggest that the risk of incident diabetes is 37-60% greater for individuals with depressive symptoms than individuals without depressive symptoms. [3] [4] [5] The mechanisms linking depression and type 2 diabetes are not well understood though it is likely that behavioral and biological factors contribute to this association. For example, various lifestyle-related behaviors such as smoking, physical inactivity and poor diet are associated with depression and can contribute to the development of prediabetes and type 2 diabetes. 6 Indeed, health behaviors are important components of various diabetes risk scores. [7] [8] [9] [10] Metabolic dysregulation, often described by the clustering of three or more metabolic traits such as high triglycerides, low highdensity lipoprotein cholesterol, high blood pressure, abdominal obesity and impaired glucose regulation, has been used as a method of identifying individuals at an increased risk of type 2 diabetes. 11 Depression accompanied by metabolic dysregulations has been identified as a subtype of depression 12, 13 and has been labeled 'metabolic depression'. 14, 15 It is possible that individuals with comorbid metabolic dysregulations and depression might be at particular risk of developing type 2 diabetes. For example, these individuals have more problems with lifestyle modifications 16 (motivation and adherence) than people with metabolic dysregulations only, or they may have more biological and metabolic risk factors than individuals with depression only.
Although depression and metabolic factors have each been demonstrated to increase the risk of type 2 diabetes, the extent to which the combination of these factors (that is, metabolic depression) increases risk of type 2 diabetes is unknown. Using data from a community sample of adults aged 40-69 years without diabetes at baseline, our aim was to identify the association between depressive symptoms, metabolic dysregulations and type 2 diabetes over 4.5 years while controlling for other non-metabolic diabetes risk factors (family history of diabetes, sociodemographic characteristics and lifestyle-related behaviors). We hypothesized that individuals with both depressive symptoms and metabolic dysregulations at baseline would have a higher risk of diabetes than those with depressive symptoms only and those with metabolic dysregulations only.
MATERIALS AND METHODS

Design/setting and participants
The Emotional Health and Wellbeing Study (EMHS) is a follow-up of 2525 adults who participated in the CARTaGENE (CaG) study in the province of Quebec, Canada. A detailed description of the CaG study is provided elsewhere. 17 Briefly, CaG recruited 20 004 participants aged 40-69 years from four metropolitan areas between July 2009 and October 2010 and detailed health, lifestyle and sociodemographic information, physiological measures and biological samples were collected.
A stratified subsample of CaG participants who: agreed to be contacted for a follow-up study, did not have diabetes at baseline and had information on depressive symptoms were contacted and invited to participate in the EMHS 4-5 years after the baseline assessment. A two-way stratification approach based on the presence of depressive symptoms and metabolic dysregulation was used. Depressive symptoms were defined as having a Patient Health Questionnaire (PHQ)-9 summary score of 6 and higher, 18 which includes mild, moderate and severe depressive symptoms. Classification for metabolic dysregulation was based on current definitions of the metabolic syndrome, and was defined as three or more metabolic risk factors, 19 including: elevated blood pressure (4130/85 mm Hg or use of anti-hypertensive medication), impaired glycemic control (HbA1c between 5.7 and 6.5%), low high-density lipoprotein cholesterol (o1.03 mmol l − 1 in men and o1.30 mmol l − 1 in women), elevated triglycerides (41.7 mmol l − 1 ) and central obesity (waist circumference ⩾ 102 cm (men), ⩾ 88 cm (women)). EMHS participants were recruited from the four groups (a) neither no/mild depressive symptoms nor metabolic dysregulation (n = 9491 in CAG database) (reference group); (b) metabolic dysregulation without depressive symptoms (n = 5193 in CAG database); (c) depressive symptoms without metabolic dysregulation (n = 1635 in CAG database); and (d) presence of both depressive symptoms and metabolic dysregulation (n = 1179 in CAG database). All participants in groups (c) and (d) and random samples of groups (a) and (b) were invited to participate. A detailed description of the sampling is provided in Figure 1 .
Potential participants were initially contacted by email and followed up by mail and phone by the CaG group. They were informed about the aims of the EMHS study and provided informed consent (written or electronic consent on a secure website) if they were interested in being contacted by EMHS investigators for a follow-up interview. Participants who agreed to be contacted by the EMHS team were contacted via telephone between October 2014 and March 2015 by trained interviewers. All participants received a detailed explanation of the study and were asked for verbal informed consent. The Douglas Mental Health University Institute Ethics Board (EMHS investigators) and the St Justine Hospital Research Ethics Board (CaG investigators) approved the consent procedures and the study protocol.
Measures
Self-reported diabetes was the central outcome variable. It was measured with the self-report question, 'In the past 5 years, has a doctor told you that you have diabetes?'. Additional information on diabetes was collected, including date of onset, current diabetes treatment (oral medication, insulin treatment and diet) and tests for HbA1c levels. This information was used to validate self-reported diabetes onset.
Depressive symptoms were measured with the PHQ-9 at baseline. Individuals were asked to what extent they had experienced each of nine depressive symptoms over the past two weeks. Possible responses range from 'not at all (0)' to 'on nearly every day (3)'. A summary score was computed from the nine individual items, with higher scores indicating greater depression symptom severity. Reliability and validity of the PHQ-9 have indicated that it has sound psychometric properties. The lifetime version of the CIDI collects information on age at the most recent episode and age at first onset. Age at first onset was used to determine whether an episode of depression had occurred before or after baseline assessment.
Physical activity at baseline was measured using the International Physical Activity Questionnaire, an instrument which has shown to have good test-retest reliability and moderate convergent validity with accelerometers. 22 Energy expenditure, measured as Metabolic Equivalent, was estimated. 23 Smoking status at baseline was assessed by two questions: 'Do you currently smoke cigarettes?' and 'In your lifetime have you smoked a total of 100 cigarettes or more?'. Smoking was categorized into three groups (current smoker, former smoker and never smoker). Participants were asked how many servings of vegetables (fresh, frozen, canned or cooked) and fruit they eat on a typical day (serving was defined as ½ cup or 125 ml). A binary diet variable was defined as consuming five or more servings of fruits and vegetables daily. 24 Medication intake was assessed during the baseline interview. Antidepressant medications were identified from the list of medications.
The CARTaGENE baseline survey collected data on sociodemographic characteristics. Education was categorized into three categories (less than high school, high school, and college/graduate studies/university). Ethnicity was classified into white vs non-white. Family history of diabetes was assessed by asking questions about parents' and siblings' histories of diabetes.
Analyses
In the first step, we used the PHQ-9 for the assessment of depressive symptoms and compared diabetes incidence for the four groups described above. Logistic regression models were used to estimate the adjusted odds ratios and 95% confidence intervals of diabetes incidence for those with (i) neither no/mild depressive symptoms nor metabolic dysregulation (reference group); (ii) metabolic dysregulation without depressive symptoms; (iii) depressive symptoms without metabolic dysregulation; and (iv) presence of both depressive symptoms and metabolic dysregulation.
Adjustment was made for age, sex, education, ethnicity, family history of diabetes, smoking, diet and physical activity. All covariates were measured at baseline. We generated multiple imputed values for the missing data from the variables used in the analysis (PROC MI and PROC MIANALYSE in SAS 9.3). To account for the stratified sampling, we determined sampling weights, defined as 1/sampling fraction, for each depression/metabolic dysregulation group and incorporated them into the analyses.
Interaction between depressive symptoms and metabolic dysregulation was assessed as departure from additive risks and quantified using Rothman's Synergy Index. 25 The Synergy Index is calculated as the ratio between combined effect and individual effects:
where AB is the presence of both depressive symptoms and metabolic dysregulation, Ab is the presence of depressive symptoms only and aB is the presence of metabolic dysregulation. A value greater than 1 implies synergism (departure from additive risks). 25 In the second step, we used structural equation modeling 26 to determine the joint associations of depression and metabolic risk factors on diabetes incidence. Structural equation models are an extension of regression analysis that can handle measurement error and a wider range of relationships among variables. Both depression and metabolic dysregulation were modeled as latent variables. Those latent variables summarize the information measured with the observed variables and account for measurement error and the individual contribution of each measure. 26 Antidepressant medication, PHQ-9 summary score and depression history (based on CIDI interview) at baseline were used as indicators for depression. Elevated blood pressure, impaired glycemic control, low high-density lipoprotein cholesterol, elevated triglycerides and central obesity were used as indicators for the latent variable metabolic dysregulation. Diabetes incidence was entered as a manifest variable. We controlled for the same baseline variables as in our logistic regression analyses. We first specified a model without interaction between depression and metabolic dysregulation, followed by a model that included an interaction term between the two latent variables (multiplicative interaction). Models were compared for fit using the Akaike Information Criterion (AIC) and the Sample-Size Adjusted Bayesian Information Criterion (BIC) and a Wald test was used for model comparison. 27 Parameters were estimated using a maximum likelihood estimation, including estimating a random effect and maximum likelihood estimator with robust standard errors. The estimated path coefficients from the latent variables to the diabetes incidence variable can be interpreted as odds ratios. Analyses were conducted with MPlus (Version 7.3). 28 Code availability All relevant computer code, necessary to reproduce our results, can be obtained by the authors upon request.
RESULTS
A total of 2525 individuals participated in the follow-up assessment. Sociodemographic and clinical characteristics of participants in our cohort and the original CARTaGENE cohort were similar, although EMHS participants had a somewhat higher educational level. Results are presented in Table 1 . Mean follow-up time was 4.6 years (s.d. = 0.30). The mean age at baseline was 53.9 (s.d. = 7.5) years and the proportion of women was 57.4%. Baseline characteristics are presented in Table 2 .
There were 760 (30.1%) participants in group a (no/mild depressive symptoms and no metabolic dysregulation) (reference group); 734 (29.1%) participants in group b (metabolic dysregulation without depression); 595 (23.6%) participants in group c A total of 87 (3.5%) individuals developed diabetes between the baseline assessment and the follow-up assessment. Diabetes incidence in the four groups was 0.9%, 4.6%, 1.5% and 8.5%, respectively. Table 2 shows results that were obtained from unadjusted and adjusted logistic regression analyses. Those without depression and without metabolic dysregulation at baseline were defined as the reference category. Metabolic dysregulation without depressive symptoms was associated with an increased risk for diabetes incidence in both unadjusted (odds ratio = 5.23) and adjusted (odds ratio = 4.40) models. Depressive symptoms without metabolic dysregulation were no longer significantly associated with diabetes incidence when controlling for other diabetes risk factors. Participants with both depressive symptoms and metabolic dysregulation had the highest risk for diabetes incidence. The Synergy Index for the adjusted model was 1.52 (95% confidence interval: 1.07-2.17), suggesting that the combined effect of depressive symptoms and metabolic dysregulation is greater than the sum of the individual effects.
In sensitivity analyses, we excluded participants with high waist circumference (top percentile of the empirical distribution: ⩾ 120 cm (men) and ⩾ 108 cm (women)) to ensure comparable waist circumference for those with metabolic dysregulation and depressive symptoms (that is, group d) and those with metabolic dysregulation without depressive symptoms (that is, group b). This did not provide substantially different results from our main analyses (data not shown) ( Table 3) .
The structural equation model containing the interaction between the latent variables representing depression and metabolic dysregulation had better fit than the model without the interaction. The Wald tests also indicated better fit for the model with interaction (P o 0.05). The structural equation model with the latent variables interaction and corresponding path coefficients and odds ratios is presented in Figure 2 .
For the measurement portion of the model, when setting impaired glycemic control as the reference, all metabolic indicators were significant for the latent variable metabolic dysregulation. When setting antidepressant medication as the reference, both depressive symptoms (PHQ-9) and major depression history (CIDI interview) were significant for the latent variable depression. Path coefficients between the latent variable and the indicators can be interpreted as regression coefficients. For the structural equation model, there was a significant depressionmetabolic dysregulation association (odds ratio = 1.59, 95% confidence interval: 1.05-2.41) and a significant main effect for metabolic dysregulation but not for depression.
DISCUSSION
In this prospective community study of 2525 individuals aged 40-69 years without type 2 diabetes at baseline, we evaluated the impact of depression and metabolic dysregulations on type 2 diabetes incidence over approximately 4.5 years. The results suggest an interaction between these two factors in relation to an increased risk of type 2 diabetes. Logistic regression analyses suggested that individuals with both depressive symptoms and metabolic dysregulations at baseline were at higher risk for developing diabetes than participants with either one of the conditions only. The combined effect of the two conditions appeared to be more than the sum of the individual effects, as suggested by the Synergy Index (additive interaction). It has been emphasized that measuring effects on the additive scale is most appropriate for prevention and for assessing the public health relevance of an exposure, as the additive scale indicates whether the effect of a risk factor would be greater in one subpopulation than in another. 29 Departure from additivity is also used to study biological interaction, which is defined as two causes acting in the same sufficient-component model to cause disease. 30 A multiplicative interaction between depression and metabolic dysregulation was also suggested by a structural equation model in which depression was defined based on a clinical interview, a symptom scale and antidepressant medication. The structural equation model takes measurement error into account and allows a more flexible modeling. Abbreviation: PHQ-9, Patient Health Questionnaire-9.
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To our knowledge, this is the first prospective community study designed to estimate the joint effect of depression and metabolic dysregulations on incident type 2 diabetes in individuals aged 40-69 years.
The main strengths of the study are the prospective design, the availability of metabolic factors at baseline, a clinical interview for the assessment of depression history and the stratified sampling. Strengths of the analysis include a structural equation modeling approach. This method has several advantages: (i) depression and metabolic dysregulation were modeled as continuous latent constructs rather than categorized summary scores, which reduces potential misclassification associated with cutoff points for binary or categorical variables; (ii) we assumed that latent constructs were measured with measurement error; that is, depression and metabolic dysregulation were not assumed to be perfectly measured by the indicators; (iii) different indicators for the two latent constructs had different weights (estimated coefficients in Figure 2) ; and (iv) all parameters were estimated simultaneously in one model. The structural equation approach permitted consideration of a depression construct that is more general than depressive symptoms in the past 2 weeks, as measured by the PHQ-9; we modeled depression as a latent variable where current depressive symptoms, antidepressant medication and major depression history based on a structured diagnostic interview were included as indicators for the depression construct.
We acknowledge several study limitations. Diabetes incidence was based on self-reports and not on clinical measures. Individuals with undiagnosed diabetes were not identified. There is the possibility that some individuals with undiagnosed diabetes might have higher levels of depressive symptoms. Nonetheless, evidence from clinical and population-based studies suggests that self-reported diabetes is a robust exposure measure 31, 32 and, in general, a sufficiently accurate measure of diabetes in epidemiologic studies. 33 Depressive symptoms at baseline were assessed using a brief self-report scale that measures depressive symptoms experienced in the past 2 weeks and does not account for history and treatment of depression. A clinical interview for depression (history) was conducted at follow-up assessment only and might be subject to recall bias. In addition, lifestyle-related behaviors such as smoking, diet and physical activity were assessed by self-report, which may be subjected to reporting bias. We cannot exclude the possibility that selection bias might have affected the strength of the association. Awadalla et al.
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found an overall concordance in the distribution of sociodemographic characteristics between the CaG cohort and the general population, although CaG participants were generally more educated. Furthermore, those people who took part in the CaG study were likely healthier than the overall cohort owing to the restrictions placed upon eligibility for blood assessments. Finally, as in all observational studies, there could be unmeasured confounding by unknown or unmeasured predictors. There are several ways in which depression or depressive symptoms may be associated with an increased risk of developing type 2 diabetes. Metabolic factors might have a key role in this association. Metabolic dysregulations are important and well-established risk factors for diabetes and require a variety of self-management behaviors to optimize treatment. The management of metabolic dysregulations often includes increasing physical activity, changing one's diet and smoking cessation. Depression has been shown to adversely impact these self-management behaviors, 16 which might worsen the management of metabolic factors. In addition, depression has been shown to be associated with poor adherence to medication. 34 It is likely that depressive symptoms and metabolic dysregulations interact with each other in a dynamic way: depressive symptoms can impede people from managing their metabolic conditions as effectively as they need to, which can lead to more metabolic problems, which, in turn, can result in more depressive symptoms. 35 Metabolic dysregulations and depression also share common pathophysiologic mechanisms 36 and the co-occurrence of both conditions might amplify the risk of developing diabetes. Depression is associated with sympathetic nervous system activation and dysregulation of the hypothalamic-pituitary-adrenocortical axis, 37 which are associated with metabolic changes through abdominal fat accumulation, glucose metabolism and blood pressure regulation. Some antidepressant medications can cause weight gain and obesity 38 and are associated with an increased risk of diabetes. 38 Increased levels of inflammatory cytokines (for example, C-reactive protein and interleukin 6) 39 are also associated with both metabolic dysregulation and depression. Depression and metabolic dysregulation might stimulate each other's occurrence, which can in turn result in several metabolic dysregulations. This can lead to a vicious cycle that further aggravates depression and metabolic outcomes. 14 For example, Vogelzangs et al. 40 have shown that metabolic dysregulations predicted a more chronic course of depressive disorders. Recurrent or chronic depressive symptoms are associated with prolonged exposure to psychosocial and normal life stress, which can wear and tear different circulatory, inflammatory, immune and psychological regulatory systems 41, 42 and increase allostatic load (the price the body pays for being forced to adapt to adverse psychosocial or physical situations). 41 Depression is a heterogeneous condition. Data-driven techniques have confirmed that depression can generally be divided into several subtypes. 43 Lamers et al. 44 identified three depressive subtypes within a cohort of subjects with depression using latent class analysis (severe melancholic class, 46%; severe atypical class, 25% and moderate severity, 29%). The severe atypical class was associated with more metabolic dysregulations, suggesting that that this subtype involves a metabolic component. Depression subtypes with metabolic components have also been reported by others. 12, 45 Although many studies and meta-analyses have shown that depression is associated with increased diabetes incidence, depression alone might not be the focal point of the problem, but rather the combination of depression with metabolic dysregulations. It might be crucial for a better understanding of depression as a risk factor for diabetes and for future prevention interventions to identify and focus on homogeneous depression phenotypes that take biological correlates into account.
CONCLUSIONS
In conclusion, our study conducted in a community sample highlights the interaction between depressive symptoms and metabolic dysregulation as a potentially important risk factor for type 2 diabetes. Early identification, monitoring and a comprehensive management approach of both conditions might be an important diabetes prevention strategy.
